Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method

A method of screening for liver cancer NAFLD-associated malignancies in a patient, said method comprising the steps of:

• (a) obtaining a biological sample from a patient;
• (b) providing a plurality of detector devices, wherein each detector device comprises a plurality of detection reagents which specifically binds to an analyte, selected from the group consisting of glucose, cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and combinations thereof, further wherein the detection reagent is selected from the group consisting of polyclonal antibodies, monoclonal antibodies;
• synthetic mono-, oligo- and polysaccharides;
• lectins;
• avidin and streptavidin;
• biotin;
• and combinations thereof,
• wherein the binding of detection reagent to analyte provides a visual indication of the presence and level of analyte in the sample,
• (c) applying the sample to at least one of the plurality of detector devices, and
• (d) ascertaining the presence and level of analyte in said sample,
• wherein the screening is positive for NAFLD-associated malignancies if elevated levels of at least three of the analytes selected from the group consisting of glucose, cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) relative to a predetermined reference range and/or control sample analyte are detected.